Page 9 - Celcuity Inc News Today

MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients

Brokerages predict that Celcuity Inc. (NASDAQ:CELC – Get Rating) will post earnings of ($0.51) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Celcuity’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.45). Celcuity posted earnings of ($0.25) per share in the same quarter […]

Celcuity Inc. (NASDAQ:CELC – Get Rating) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages […]

Celcuity (NASDAQ:CELC – Get Rating) issued its earnings results on Wednesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07), Fidelity Earnings reports. During the same quarter last year, the business posted ($0.25) earnings per share. Celcuity stock traded up $0.39 during mid-day trading on Friday, hitting $8.35. […]

Finalized pivotal Phase 3 trial design following formal meetings with FDAReceived FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancerPresented updated Phase 1b data during

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients

Celcuity Inc. (NASDAQ:CELC – Get Rating) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price […]

MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients

Patients who received prior treatment with a CDK4/6 inhibitor > 2 prior therapies for ABC: 33% of patients ORR: 63% ... | December 10, 2021

78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D)MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc.